UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

English Journal

Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia.

Rosales A, Alvear M, Cuevas A, Saavedra N, Zambrano T, Salazar LA.SourceCentro de Biología Molecular & Farmacogenética, Departamento de Ciencias Básicas, Facultad de Medicina, Universidad de La Frontera, Av. Francisco Salazar 01145, Casilla 54-D, Temuco, Chile.
Clinica chimica acta; international journal of clinical chemistry.Clin Chim Acta.2012 Feb 18;413(3-4):495-501. Epub 2011 Nov 19.
BACKGROUND: Statins are normally the first-line therapy for hypercholesterolemia (HC); however, the lipid-lowering response shows high interindividual variation. We investigated the effect of four polymorphisms in CYP3A4, CYP3A5 and ABCB1 genes on response to atorvastatin and CYP3A4 activity in Chil
PMID 22120734

Treatment of familial hypercholesterolemia: is there a need beyond statin therapy?

Raper A, Kolansky DM, Cuchel M.SourceInstitute of Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, 3600 Spruce Street, Philadelphia, PA, 19104, USA.
Current atherosclerosis reports.Curr Atheroscler Rep.2012 Feb;14(1):11-6.
Familial hypercholesterolemia (FH) is a genetic lipid disorder that is characterized by severely elevated cholesterol levels and premature cardiovascular disease. Both the heterozygous and homozygous forms of FH require aggressive cholesterol-lowering therapy. Statins alone frequently do not lower t
PMID 22135161